# MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/md1003-high-dose-biotin-for-the-treatment-of-progressive-multiple-sclerosis-a/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ayman Tourbah,Christine Lebrun‐Frénay,Gilles Edan,Michel Clanet,Caroline Papeix,Sandra Vukusic,de Sèze,Marc Debouverie,Olivier Gout,Pierre Clavelou,Gilles Defer,David Laplaud,Thibault Moreau,Pierre Labauge,Bruno Brochet,Frédéric Sedel,Jean Pelletier,on behalf of the MS-SPI study group |
| Citations | 288 |
| DOI | 10.1177/1352458516667568 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://journals.sagepub.com/doi/pdf/10.1177/1352458516667568 |
| OpenAlex ID | https://openalex.org/W2510859603 |
| PMID | 27589059 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Caroline Papeix](https://scholariq.org/researchers/caroline-papeix/)

## Paper primary topic

- [Biotin and Related Studies](https://scholariq.org/topics/biotin-and-related-studies/)

## Paper topics

- [Biotin and Related Studies](https://scholariq.org/topics/biotin-and-related-studies/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Biochemical and Structural Characterization](https://scholariq.org/topics/biochemical-and-structural-characterization/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.